• At the American College of Cardiology 2026 Annual Scientific Sessions, iRhythm Technologies reported favorable analysis results for its Zio cardiac monitoring device and introduced iRhythm Academy, an education platform for healthcare professionals in cardiac monitoring.
• The new data highlighting clinically actionable arrhythmias in patients with chronic kidney disease, diabetes, and severe obesity could reinforce Zio’s relevance in managing high‑risk, comorbid populations.
• We’ll now explore how the positive Zio clinical data and launch of iRhythm Academy may influence iRhythm’s broader investment narrative.

AI is about to change healthcare. These 34 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

iRhythm Holdings Investment Narrative Recap

To own iRhythm, you have to believe Zio can remain a differentiated standard in ambulatory cardiac monitoring while the company steadily improves profitability. The ACC.26 data and launch of iRhythm Academy strengthen the clinical and educational story, but they do not directly resolve nearer term issues such as competitive pressure, reimbursement uncertainty, and the need to turn recent revenue growth into durable, GAAP profitability.

The ACC.26 announcement is especially relevant because it expands Zio’s evidence base in high risk chronic kidney disease, diabetes, and severe obesity populations while introducing iRhythm Academy to deepen clinician engagement. Together, these could support higher utilization among complex patients and help defend pricing and reimbursement at a time when industry margin pressure and regulatory scrutiny remain key swing factors for the stock.

However, against this encouraging clinical backdrop, investors should still pay close attention to the unresolved regulatory and reimbursement risks that could...

iRhythm Holdings' narrative projects $1.2 billion revenue and $66.5 million earnings by 2029.

Uncover how iRhythm Holdings' forecasts yield a $199.57 fair value, a 68% upside to its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts were already more cautious, assuming revenue of about US$1.2 billion and earnings near US$59.0 million by 2029, and worrying that slower EHR driven adoption in primary care could cap growth, which shows how differently you and other investors might weigh the new ACC.26 data and adoption risks.

Explore 3 other fair value estimates on iRhythm Holdings - why the stock might be worth as much as 89% more than the current price!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your iRhythm Holdings research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free iRhythm Holdings research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate iRhythm Holdings' overall financial health at a glance.

Seeking Other Investments?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• Find 58 companies with promising cash flow potential yet trading below their fair value.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 19 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• The latest GPUs need a type of rare earth metal called Terbium and there are only 32 companies in the world exploring or producing it. Find the list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.